A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.41 which represents a slight increase of $0.07 or 5.22% from the prior close of $1.34. The stock opened at $1.37 and touched ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.22 which represents a slight increase of $0.08 or 7.02% from the prior close of $1.14. The stock opened at $1.2 and touched a ...

In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.